The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline.
Banner Health hires renowned leader for new biomarker research program
Nicholas Ashton’s program aims to discover, galvanize use of new blood tests in fight against Alzheimer’s and related diseases PHOENIX (May 15, 2024) – Emerging blood tests have begun to revolutionize the fight against Alzheimer’s disease, the most common cause of...